test

Alessandro D. Santin MD

Professor of Obstetrics, Gynecology, and Reproductive Sciences; Clinical Research Program Leader, Gynecologic Oncology Program, Yale Cancer Center

Research Interests

Mutational landscape of gynecolocic tumors; Therapeutic vaccine development for gynecologic malignancies; Tumor immunology; Immunotherapy; Tumor angiogenesis; Radiation biology; Experimental therapeutics in gynecologic oncology


Research Summary

Dr. Santin is a skilled gynecologic oncologist and talented clinical scientist who has a strong background in training and mentoring talented young physician-scientists. Dr. Santin’s research and clinical accomplishments have been published in high-impact journals in the cancer research field, including the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, and the Journal of Virology, while numerous additional publications have been reported in subspecialty journals.

Dr. Santin’s translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. He is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma. His research program spans a range from basic studies in molecular cancer genetics and tumor immunology to translational clinical cancer research testing novel immunotherapeutic strategies and targeted compounds in vivo for the treatment of gynecologic malignancies.

Extensive Research Description

Dr. Santin is a skilled gynecologic oncologist and talented clinical scientist who has a strong background in training and mentoring talented young physician-scientists. He has been involved in the training of 15 post-doctoral fellows, including Gynecologic Oncology, Medical Oncology and Surgical Oncology Fellows, the majority of whom have gone on to academic careers in the U.S. and abroad in Gynecologic Oncology and cancer research.

Dr. Santin’s research and clinical accomplishments have been published in high-impact journals in the cancer research field, including the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, and the Journal of Virology, while numerous additional publications have been reported in subspecialty journals. Dr. Santin’s translational research program in ovarian cancer has been funded multiple times by federal agencies including the Department of Defense (DoD), the National Institute of Health (NIH) as well as private National and International Foundations. He is currently funded by NIH to evaluate the potential use of Clostridium Perfringens Enterotoxin (CPE) as a novel therapy against chemotherapy resistant ovarian carcinoma.

His research program spans a range from basic studies in molecular cancer genetics and tumor immunology to translational clinical cancer research testing novel immunotherapeutic strategies and targeted compounds in vivo for the treatment of gynecologic malignancies. Dr. Santin is an active member of the Gynecologic Oncology Group (GOG) and the International Gynecological Cancer Society (IGCS), the two largest organizations of gynecologic oncologists in the world. He is a member of the GOG Developmental Therapeutics Committee, a national Committee that reviews multi-site concepts/protocols to be implemented at nationwide level by the GOG funded by the NIH and he is Chairman for the entire GOG of multiple Phase II clinical studies testing novel biologic agents in patient harboring gynecologic malignancies.

Dr. Santin has initiated and completed multiple investigator’s initiated FDA approved clinical trials in gynecologic patients using novel immunotherapeutic strategies developed and characterized in his own laboratory. Dr. Santin has been awarded multiple patents for the development of new methods for the early diagnosis of ovarian cancer as well as the development of novel immunotherapeutic methods targeting serine proteases highly expressed in ovarian cancer patients.

Dr. Santin also serves as peer reviewer for a number of journals including Lancet, Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research, American Journal of Obstetrics&Gynecology, International Journal of Cancer, British Journal of Cancer, Gynecologic Oncology, International Journal of Radiation Oncology, Obstetrics&Gynecology, Journal of Immunotherapy, International Journal of Gynecological Cancer, Cancer Immunology Immunotherapy, BMC Cancer, Cancer Detection&Prevention, Molecular Cancer Research, Cancer, Cancer Biology & Therapy, Reproductive Sciences.


Selected Publications

  • Bellone S. Roque D. Cocco E. Gasparrini S. Bortolomai I. Buza N. Abu-Khalaf M. Silasi DA. Ratner E. Azodi M. Schwartz PE. Rutherford TJ. Pecorelli S. Santin AD. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy. British Journal of Cancer. 106(9):1543-50, 2012
  • Santin AD, Sill MW D. McMeekin D.S, Leitao MM, Jubilee Brown J, Sutton GP, Van Le L,Griffin P, Boardman CH, Phase II trial of Cetuximab in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Gynecol Oncol 122(3):495-500, 2011.
  • Casagrande C, Cocco E, Bellone S, Richter CE, Bellone M, Todeschini P, Siegel E, Varughese J, Silasi D-A, Azodi M, Rutherford TJ, Pecorelli S, Schwartz PE, Santin AD. Eradication of Chemotherapy-Resistant CD44+ Human Ovarian Cancer Stem cells in Mice by Intraperitoneal Administration of Clostridium Perfringens-Enterotoxin (CPE). Cancer. 117(24):5519-28, 2011.
  • El-Sahwi K, Bellone S, Cocco E, Cargnelutti M, Casagrande F, Bellone M, Abu-Khalaf M, Buza N, Tavassoli FA, Hui P, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. British Journal of Cancer. 102(1):134-43, 2010.
  • El-Shawi K, Bellone S, Cocco E, Casagrande F, Bellone M, Abu-khalaf M, Buza N, Tavassoli FA, Hui P, Ruttinger D, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-Specific immunotherapy with human monoclonal antibody Adecatumumab (MT201). Mol Cancer Ther, 9(1): 58-66, 2010.
  • Cocco E, Bellone S, El-Shawi K, Cargnelutti M, Buza N, Tavassoli FA, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Serum amyloid A: a novel biomarker for uterine serous papillary cancer. British Journal of Cancer, 101(2):335-41, 2009.
  • Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J Virology, 83(13)6779-89, 2009.
  • Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel EE, Roman JJ, Burnett A, Pecorelli S, Cannon MJ. Human Papillomavirus 16/18 E7-Pulsed Dendritic Cell Vaccination in Stage IB-IIA Cervical Cancer Patients; A Phase I Escalating Dose Trial. Journal of Virology, 82(4):1968-79, 2008.

Edit Profile